CD274 and neoplasm: It has been demonstrated that TREM-1+ TAMs respond to hypoxia and tumor metabolites via the ERK/NF-kb pathway, leading to the accumulation of CCR6+ Foxp3+ Treg and promoting HCC resistance to PD-L1 treatment [89].